Economic Impact of Clozapine Treatment Persistence: A Canadian Perspective


Mathurin K1, Bloom D2, Gross JA3, Lachaine J1
1PeriPharm Inc., Montreal, QC, Canada, 2Douglas Mental Health University Institute, Montreal, QC, Canada, 3HLS Therapeutics Inc., Toronto, ON, Canada

OBJECTIVES: Clozapine is widely used for treatment-resistant schizophrenia (TRS). Clozapine manufacturers are required to implement a patient support program, but not all are equal. The objective of this study was to estimate the economic impact of clozapine persistence on brand vs. generic clozapine, in Quebec, Canada.

METHODS: A retention analysis of brand clozapine versus generic clozapine products was performed using IQVIA Canada’s Régie de l’assurance maladie du Québec (RAMQ) data. Patients identified were followed for the subsequent 18 months. Costs considered were those associated with treatment acquisition, hospitalization, suicide attempts, emergency room and physician visits, and withdrawal symptoms. Costs were obtained from literature and Canadian governmental sources.

RESULTS: The 18-month persistence rate of patients on brand clozapine was 32.5% better than patients on generic clozapine, with the absolute percentages being 69.2% vs 55.4% (p=0.049). The improved persistence on brand clozapine compared to generic translates into savings of $3,158 per patient, per year, despite higher treatment acquisition costs on brand clozapine (+$2,097) and the longer retention, mainly owing to the reduced hospitalization (-$4,825). When applying these savings to the total Quebec TRS patient population on clozapine, this represents total savings of $25.6 million.

CONCLUSIONS: The results support, that if one assumes two different formulations may have the same clinical benefits, the support programs associated with the manufacturer’s registries and support systems have an impact on improving overall persistence on treatment.

Conference/Value in Health Info

2023-05, ISPOR 2023, Boston, MA, USA

Value in Health, Volume 26, Issue 6, S2 (June 2023)




Economic Evaluation, Health Policy & Regulatory

Topic Subcategory

Pricing Policy & Schemes, Public Spending & National Health Expenditures


Generics, Neurological Disorders

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on Update my browser now